Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley Sells 1,000 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 1,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $18.84, for a total value of $18,840.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Patrick J. Haley also recently made the following trade(s):

  • On Monday, August 12th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $20.39, for a total value of $20,390.00.
  • On Tuesday, August 6th, Patrick J. Haley sold 25,000 shares of Exelixis stock. The shares were sold at an average price of $20.02, for a total value of $500,500.00.
  • On Wednesday, July 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $20.96, for a total value of $20,960.00.

Shares of NASDAQ EXEL opened at $19.26 on Friday. Exelixis, Inc. has a twelve month low of $13.42 and a twelve month high of $25.31. The stock’s 50 day moving average price is $20.28 and its 200-day moving average price is $21.26. The company has a market capitalization of $5.83 billion, a PE ratio of 13.47 and a beta of 2.04. The company has a quick ratio of 8.53, a current ratio of 8.64 and a debt-to-equity ratio of 0.02.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. Exelixis had a return on equity of 31.31% and a net margin of 70.52%. The firm had revenue of $240.28 million for the quarter, compared to the consensus estimate of $226.97 million. During the same quarter in the previous year, the business earned $0.31 EPS. The company’s revenue was up 29.1% compared to the same quarter last year. As a group, research analysts expect that Exelixis, Inc. will post 0.92 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Fulton Breakefield Broenniman LLC lifted its stake in Exelixis by 3.8% in the second quarter. Fulton Breakefield Broenniman LLC now owns 15,399 shares of the biotechnology company’s stock valued at $329,000 after purchasing an additional 560 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its stake in Exelixis by 1.1% in the second quarter. Municipal Employees Retirement System of Michigan now owns 55,490 shares of the biotechnology company’s stock valued at $1,186,000 after purchasing an additional 600 shares during the last quarter. First Mercantile Trust Co. lifted its stake in Exelixis by 10.9% in the second quarter. First Mercantile Trust Co. now owns 6,386 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 627 shares during the last quarter. MetLife Investment Advisors LLC lifted its stake in Exelixis by 0.4% in the first quarter. MetLife Investment Advisors LLC now owns 182,944 shares of the biotechnology company’s stock valued at $4,354,000 after purchasing an additional 642 shares during the last quarter. Finally, Cornerstone Advisors Inc. lifted its stake in Exelixis by 28.4% in the second quarter. Cornerstone Advisors Inc. now owns 3,099 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 686 shares during the last quarter. Institutional investors and hedge funds own 77.41% of the company’s stock.

A number of equities analysts have recently weighed in on the company. Cowen set a $25.00 target price on Exelixis and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Stifel Nicolaus boosted their target price on Exelixis from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Tuesday, August 6th. BidaskClub downgraded Exelixis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. Finally, ValuEngine downgraded Exelixis from a “hold” rating to a “sell” rating in a research note on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. Exelixis currently has an average rating of “Hold” and a consensus price target of $27.75.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

See Also: What is a trade deficit?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.